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Introduction 
The  synthesis  of  new  carbapenem  remain  an  area  of 
intense  research  because  of  the  broad-spectrum 
antibacterial  activity  of  this  chemical  class.
1-3 
Doripenem  is  a  recently  released  antibiotic  with 
significant  potential  for  use  in  Pseudomonas 
aeruginosa infections occur in CF and burn patients.
4 
The  In  vitro  antimicrobial  activity  of  Doripenem,  is 
generally  comparable  to  that  of  meropenem  and 
imipenem  although  it  is  more  active  against  Gram-
negative  organisms  than  imipenem.
5  The  activity  of 
doripenem  against  P.  aeruginosa  isolates  is  slightly 
better  than  that  of  other  carbapenems.  However, 
development  of  carbapenem  resistance  may 
significantly compromise their efficacy.
6 Resistance to 
carbapenems  including  doripenem  resulted  from  the 
complex  interaction  of  several  mechanisms  including 
loss  of  the  OprD  porin,  overexpression  of  efflux 
systems  (MexAB-OprM,  MexEF-OprN)  and 
production  of  carbapenemase  activity,  usually  a 
metallo-β-lactamase (MBL).
7-10 It should be noted that 
doripenem is no less susceptible to hydrolysis by MBL 
than  are  the  other  carbapenems  and  none  of  them  is 
active against P. aeruginosa isolates harboring various 
MBL  genes.
11  Since,  there  is  no  CLSI  guideline  for 
doripenem MIC breakpoint until now, so the results of 
MIC  susceptibility  pattern  obtained  from  different 
geographical  regions  from  different  clinical  isolates 
could be helpful in this regard. 
Since,  P.  aeruginosa  is  one  of  the  most  frequently 
isolated pathogens from both CF and burn patients, we 
designed the study to determine susceptibility patterns 
of  all  the  isolates  and  to  compare  the  in  vitro 
antibacterial  activity  of  doripenem  with  that  of 
imipenem,  and  meropenem  among  non  MBL  P. 
aeruginosa isolates from both CF and burn patients. 
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Purpose:  The  antimicrobial  activity  of  doripenem  in  comparison  of  imipenem, 
meropenem and ertapenem among Pseudomonas aeruginosa isolated from burn and 
Cystic Fibrosis (CF) patients were determined. Methods: Metallo-β-lactamase (MBL) 
genes in imipenem non susceptible P. aeruginosa isolates were detected using PCR 
method.  The  in  vitro  susceptibilities  of  doripenem,  imipenem,  meropenem  and 
ertapenem were determined by Etests. MIC50 and MIC90 for corresponding antibiotics 
were determined individually in burn and CF isolates. Results: Among isolates which 
were resistant to imipenem, 16 isolates were positive for the bla IMP gene. All isolates 
had no  bla  VIM  gene. All MBL producing isolates were excluded.   MIC50/MIC90  of 
doripenem in CF and burn isolates were 0.75/>32 and >32/>32 mg/L respectively. The 
corresponding values for imipenem in CF and burn isolates were 2/>32 and >32/>32  
mg/L, respectively.  Conclusion: The susceptibility rate of doripenem is higher than 
that  of  imipenem  and  meropenem  among  P.aeruginosa  isolated  from  CF  patients, 
whereas,  there  is  no  difference  between  the  efficiency  of  doripenem  and  old 
carbapenems in non MBL producing P.aeruginosa isolates in burn patients.  
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Materials and Methods 
Bacterial Strains 
From June to December 2011, a total number of 92 non 
repetitive  P.  aeruginosa  isolates  was  enrolled  in  this 
study. Sixty three burns isolates were recovered from 
hospitalized patients in a level one burn care center and 
29 isolates were collected from CF patients admitted to 
a children’s medical center. This collection of bacteria 
was identified by conventional biochemical tests. 
 
Antimicrobial Susceptibility Testing 
The Kirby-Bauer disk diffusion method was employed 
to evaluate susceptibility of the following antimicrobial 
agents:  piperacillin/tazobactam,  aztreonam,  ticarcillin, 
trimetoprime  and  tobramycin  (MAST,  UK).  MIC 
values  of  the  imipenem,  meropenem,  ertapenem  (AB 
BIODISK,  Solna,  Sweden),  doripenem,  ceftazidime, 
cefepime,  ciprofloxacin,  amikacin,  gentamicin 
(Liofilchem, Italy) were determined by Etests. Results 
were interpreted according to Clinical and Laboratory 
Standards Institute (CLSI) criteria, where applicable
12. 
FDA  interpretive  criteria  were  applied  to  doripenem 
results (susceptible ≤ 2 mg/l for P. aeruginosa).
13 The 
results  were  examined  to  ensure  that  reported  MICs 
were within acceptable standards set by CLSI based on 
a  comparator  agent  and  the  following  ATCC  quality 
control strain, ATCC 25922 (E. coli).  
 
Ethical Standards 
Ethical  approval  to  perform  the  study  was  obtained 
from the institutional review board of Tabriz University 
of  Medical  Sciences.  Written  informed  consent  was 
obtained from all patients included in the study.  
 
MIC50 and MIC90 Calculation 
The  concentration  of  each  antimicrobial  agent,  that 
inhibited  50%  (MIC  50)  and  90%  (MIC  90)  of  the 
strains, was calculated for each of the antibiotics singly. 
The formula of geometric means was used as follows:
14 
MIC50 = (M < 50) +
(n − X) × [(M > 50)− (M < 50)]
Y
 
Where M < 50 is the MIC of the highest cumulative 
percentage  below  50%,  M  >  50  is  the  MIC  of  the 
lowest cumulative percentage above 50%; n is 50% of 
the  number  of  organisms  tested,  X  is  the  number  of 
organisms in the group at M <50, and Y is the number 
of organism in the group at M >50. 
 
Screening for Metallo Β-Lactamase (Mbl) Production 
In  order  to  identify  MBL  producing  isolates,  we 
detected non susceptible isolates against imipenem by 
Kirby-Bauer  disk  diffusion  method  using  imipenem 
disk 10 mg/L. Imipenem non susceptible isolates were 
selected  for  detection  of  IMP  and  VIM 
metalloenzymes.  Total  genomic  DNA  of  the  isolates 
which  were  resistant  to  imipenem,  was  extracted  as 
described  previously.
15  Genes  encoding  class  B 
carbapenemases were detected by PCR using specific 
primers  for  blaIMP  and  blaVIM  metalloenzyme  genes. 
The  sequences  of  primers  were  as  follows:  IMP-F1, 
(CATGGTTTGGTGGTTCTTGT),  IMP-R1, 
(GTAAGTTTCAAGAGTGATGC),  VIM-F1, 
(GTTTGGTCGCATATCGCAAC)  and  VIM-R1 
(CTACTCGGCGACTGAGCGAT).  The  generated 
PCR  products  were  524  and  623  base  pairs, 
respectively. 
 
Results 
Screening MBL Production 
PCR Screening of isolates which were non susceptible 
to imipenem indicated the presence of 17 P. aeruginosa 
isolates harboring bla IMP gene. Only one isolate among 
CF and 16 isolates among burn patients were detected 
as MBL positive isolates. There was no bla VIM carrying 
isolate  detected  in  our  study.  All  MBL  producing 
isolates were excluded to remove the effect of one of 
the  most  interfering  factors  involved  in  carbapenem 
resistance. To the best of our knowledge, our study was 
the first report of Iran that evaluated the in vitro activity 
of  doripenem  in  comparison  with  that  of  previously 
FDA approved carbapenems. 
 
Antimicrobial Susceptibility Testing 
As shown in Table 1, the Kirby-Bauer disk diffusion 
method was performed in 75 non MBL P. aeruginosa 
which comprised of 47 burn and 28 CF isolates. Table 
2, summarizes the MIC’s of some antimicrobial agents 
other  than  those  mentioned  in  Table  1.  The  tables 
showed  that  among  the  tested  comparators, 
piperacillin/tazobactam (14.9% and 93.1% susceptible, 
respectively) provided the greatest activity in both burn 
and  CF  isolates,  followed  by  tobramycin  (12.8%)  in 
burn  isolates.  The  susceptibility  rates  of  amikacin, 
imipenem, meropenem and doripenem were the same 
among  burn  isolates  (10.6%).  However,  the 
susceptibility rate of doripenem among CF isolates was 
similar to that of amikacin (89.3%) and higher than that 
of  old  carbapenems  (imipenem  &  meropenem).  The 
greatest  differences  in  the  susceptibility  rate  between 
burn  and  CF  strains  were  observed  with  doripenem 
(10.6% versus 89.3%), amikacin (10.6% versus 89.3%) 
and piperacillin/tazobactam (14.9 % versus 93.1% ).  
According to the Table 2, among CF isolates, at any 
given  MIC  concentration  from  ≤0.5  to  1.5  mg/L, 
doripenem  (MIC50,  0.75  mg/L)  inhibited  a  slightly 
greater proportion of isolates than meropenem (MIC50, 
0.75 mg/L) and notably greater than imipenem (MIC50, 
2 mg/L ). However, higher MIC levels of doripenem at 
2  and  4  mg/L,  provided  the  same  coverage  as 
meropenem,  inhibiting  85.7%  and  89.3%  of  isolates, 
respectively. Table 2  showed that  ertapenem was  the 
least  efficacious  carbapenem  (susceptibility  rate, 
66.7%) that could inhibit only 25% of CF isolates at the 
MIC level of 4 mg/L. 
On  the  other  hand,  among  burn  isolates,  all 
carbapenems  except  ertapenem  had  the  same  activity 
(MIC50  and  MIC90,  >32  mg/L).  The  proportion  of 
isolates inhibited at MIC level ≥1 mg/L of doripenem  
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and  meropenem  was  similar  (10.6%),  however,  the 
inhibition  rates  for  doripenem  at  MIC  levels  of  ≤0.5 
and  0.75  mg/L  were  slightly  higher  than  that  of 
meropenem. At any given concentration from ≤ 0.5 to 
> 32 mg/L, doripenem inhibited a remarkably greater 
proportion of isolates than imipenem (Table 2). Similar 
to CF isolates, ertapenem identified as the least potent 
agent  in  burn  isolates  which  inhibited  6.4%  of  burn 
isolates in comparison with 10.6% inhibition by other 
carbapenems. 
 
Table 1. Results of disk diffusion method on non-MBL P. aeruginosa isolates. 
Antibiotic  PTZ  ATM  TN  TM  TC 
Profile 
S 
n(%) 
NS 
n(%) 
S 
n(%) 
NS 
n(%) 
S 
n(%) 
NS 
n(%) 
S 
n(%) 
NS 
n(%) 
S 
n(%) 
NS 
n(%) 
Burn(47)  7(14.9)  40(85.1)  4(8.5)  43(91.5)  6(12.8)  41(87.2)  0  47(100)  4(8.5)  43(91.5) 
CF(28)  26(93.1)  2(6.9)  9(31)  19(69)  22(79.3)  6(20.7)  2(6.9)  26(93.1)  23(82.8)  5(17.2) 
PTZ: piperacillin/tazobactam, ATM: aztronam, TN: tobramycin, TM: trimetoprime, TC: ticarcillin, S: susceptible, NS: non susceptible. 
 
According to the susceptibility rates, the MIC levels of 
imipenem, meropenem and doripenem were completely 
in line with each other except for 3 isolates; one burn 
and  2  CF  isolates  which  showed  the  MIC  level  of 
imipenem of >32 mg/L but doripenem and meropenem 
MIC levels of ≤ 1 mg/L. 
 
Table 2. In vitro activities of doripenem and comparators against non MBL P. aeruginosa isolates in burn and CF patients. 
  MIC50  MIC90  Range (mg/L)  Susceptibility (%)  Cumuative % inhibited at MIC (mg/L) 
            ≤0.5  0.75  1  1.5  2  4  >32 
Amikacin 
CF  5.5  >256  1->256  89.3  -  -  -  -  -  -  - 
Burn  256  256  3->256  10.6  -  -  -  -  -  -  - 
Gentamicin 
CF  6.83  >256    60.7  -  -  -  -  -  -  - 
Burn  128  >128  3->256  8.5  -  -  -  -  -  -  - 
Cefepime 
CF  12.25  >256  2->256  57.1  -  -  -  -  -  -  - 
Burn  256  256  0.75->256  6.4  -  -  -  -  -  -  - 
Ceftazidime 
CF  2  >256  0.5->256  75.0  -  -  -  -  -  -  - 
Burn  256  256  2->256  8.5  -  -  -  -  -  -  - 
Ciprofloxacin 
CF  0.19  6.25  0.047->32  78.6  -  -  -  -  -  -  - 
Burn  >32  >32  0.047->32  8.5  -  -  -  -  -  -  - 
Imipenem 
CF  2  >32  0.75->32  85.7  0  7.1  14.3  39.3  60.7  85.7  100 
Burn  >32  >32  0.75->32  10.6  0  2.2  2.2  6.5  8.7  8.7  100 
Meropenem 
CF  0.75  >32  0.125->32  85.7  28.6  50.0  78.6  82.1  85.7  89.3  100 
Burn  >32  >32  0.15->32  10.6  8.5  8.5  10.6  10.6  10.6  10.6  100 
Doripenem 
CF  0.75  >32  0.094->32  89.3  39.3  75.0  82.1  85.7  85.7  89.3  100 
Burn  >32  >32  0.125->32  10.6  10.6  10.6  10.6  10.6  10.6  10.6  100 
Ertapenem 
CF  32  >32  0.094->32  66.7  3.6  3.6  3.6  7.1  10.7  25.0  100 
Burn  >32  >32  3->32  6.4  0  0  0  0  0  8.5  100 
 
Discussion 
Infections  caused  by  P.  aeruginosa  in  burn  and  CF 
patients  often  treated  with  difficulty  due  to  the 
emergence  of  resistance  and  lack  of  effective 
antibiotics.
16  Doripenem  as  a  new  carbapenem  offers 
potentially enhanced carbapenem activity but does not 
expand  the  spectrum  of  activity  of  this  class
4.  Like 
other  carbapenems,  doripenem  has  stability  against 
many  β-lactamases,  but  remains  labile  to  class  B 
enzymes,  known  as  metallo-β-lactamases.
5  Therefore, 
in the present work, we attempted to assess the in vitro 
activity of doripenem among non MBL P. aeruginosa 
isolated from CF and burn patients, in comparison with 
other carbapenems.  
Despite  the  higher  carbapenem  MIC  rates  in  our  CF 
isolates as compared with similar studies,
15,16 it can be 
concluded  that  doripenem  has  much  greater  potency 
than imipenem. Although the MIC50 of both doripenem 
and meropenem was similar, the more inhibition rate of 
25%  of  this  recently  approved  carbapenem  indicated  
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that  doripenem  could  be  considered  as  a  good 
alternative therapeutic agent in CF patients. In a recent 
similar  study,
16  antibiotic  susceptibility  of  P. 
aeruginosa  isolated  from  CF  patients,  doripenem 
showed as the most active antibiotic in the absence of 
piperacillin/tazobactam.  Totally,  it  seems  that 
doripenem  can  be  considered  as  the  most  potent 
carbapenems  against  P.  aeruginosa  infections  in  CF 
patients. 
Since, MBLs were the most important mechanisms in 
high  level  of  resistance  against  all  carbapenems,  we 
decided to exclude the MBL positive isolates to explore 
the probable difference in doripenem MIC’s versus old 
carbapenems. Although the susceptibility rates against 
doripenem in burn isolates showed no superiority to old 
carbapenems,  the  greater  population  of  isolates  were 
inhibited  at  any  concentration  of  doripenem  as 
compared  with  imipenem  and  meropenem.  Among 
burn  isolates,  all  cabapenems  have  the  same  activity 
except for ertapenem which has the least efficiency. 
We  found  3  imipenem  resistant  isolates  which  were 
susceptible  to  meropenem  and  doripenem.  This 
phenomenon  occurred  to  those  isolates  with 
nonenzymatic resistance involving loss of porin OprD 
and up-regulation of efflux pumps
13 which we intend to 
explore  in  a  further  study.  Conversely,  other 
researchers  declared  that  this  could  be  the  exception 
other than a rule with no reason.
17 
Although  ertapenem  is  not  a  representative  of 
carbapenems with the consideration of broad spectrum 
activity which can not be used to treat infections due to 
non-fermentative  Gram-negative  bacteria,
13  we 
intended  to  investigate  the  in  vitro  activity  of  this 
antimicrobial agent for the first time in Iran. Our results 
are consistent with the results of other investigators
18 
which showed the lowest susceptibility rate among all 
used carbapenems in both burn and CF isolates (6.4% 
and 66.7%). Our results corroborated by the results of 
the study conducted by Quale et al. They found only 
18%  of  P.  aeruginosa  isolates  that  were  susceptible 
against  ertapenem  while  imipenem  and  meropenem 
were more potent, inhibiting 55% and 64% of isolates 
compared to ertapenem. 
 
Conclusion 
Although doripenem is more active than imipenem and 
meropenem  against  P.  aeruginosa  isolated  from  CF 
patients, no superiority of doripenem is observed to old 
carbapenems  in  non  MBL  producer  P.  aeruginosa 
isolates  in  burn  patients.  In  terms  of  MIC  level  of 
doripenem,  this  antibiotic  is  the  most  active  but  this 
advantage  is  partly  offset  by  lower  regulatory 
breakpoints. Ertapenem is the least potent agent against 
P. aeruginosa isolates. 
 
Acknowledgments 
We are grateful to Dr. Saber Yousefi from Department 
of  Clinical  Laboratory  Medicine,  Faculty  of 
Paramedicine, Urmia University of Medical Sciences.  
This  work  was  supported  fully  by  Tabriz  Research 
Center  of  Infectious  and  Tropical  Diseases  (grant 
No.89/16),  Tabriz  University  of  Medical  Sciences, 
Tabriz, Iran.  
This  is  a  report  of  a  database  from  thesis  entitled 
“Evaluation  of  MexAB-OprM  and  MexXY-OprM 
efflux  systems,  AmpC  cephalosporinase  and  OprD 
protein  expressions    to  investigate  their  association 
with resistance against carbapenemes in Pseudomonas 
aeruginosa isolated from clinical specimens” registered 
in Tabriz University of Medical Sciences. 
 
Conflict of interest 
There is no conflict of interest in this study. 
 
References 
1.  Nomura  S,  Nagayama  A.  In  vitro  antibacterial 
activity  of  s-4661,  a  new  parenteral  carbapenem, 
against urological pathogens isolated from patients 
with  complicated  urinary  tract  infections.  J 
Chemother 2002;14(2):155-60. 
2. Ohba F, Nakamura-Kamijo M, Watanabe N, Katsu 
K. In vitro and in vivo antibacterial activities of er-
35786,  a  new  antipseudomonal  carbapenem. 
Antimicrob Agents Chemother 1997;41(2):298-307. 
3. Watanabe A, Takahashi H, Kikuchi T, Kobayashi T, 
Gomi  K,  Fujimura  S,  et  al.  Comparative  in  vitro 
activity  of  s-4661,  a  new  parenteral  carbapenem, 
and  other  antimicrobial  agents  against  respiratory 
pathogens. Chemotherapy 2000;46(3):184-7. 
4. Parkins MD, Elborn JS. Newer antibacterial agents 
and their potential role in cystic fibrosis pulmonary 
exacerbation management. J Antimicrob Chemother 
2010;65(9):1853-61. 
5.  Lascols  C,  Legrand  P,  Merens  A,  Leclercq  R, 
Armand-Lefevre  L,  Drugeon  HB,  et  al.  In  vitro 
antibacterial activity of  doripenem against  clinical 
isolates from french teaching hospitals: Proposition 
of zone diameter breakpoints. Eur J Clin Microbiol 
Infect Dis 2011;30(4):475-82. 
6.  Rodriguez-Martinez  JM,  Poirel  L,  Nordmann  P. 
Molecular  epidemiology  and  mechanisms  of 
carbapenem resistance in pseudomonas aeruginosa. 
Antimicrob Agents Chemother 2009;53(11):4783-8. 
7. El Amin N, Giske CG, Jalal S, Keijser B, Kronvall 
G, Wretlind B. Carbapenem resistance mechanisms 
in  pseudomonas  aeruginosa:  Alterations  of  porin 
oprd  and  efflux  proteins  do  not  fully  explain 
resistance  patterns  observed  in  clinical  isolates. 
Acta  Pathol  Microbiol  Immunol  Scand 
2005;113(3):187-96. 
8. Wolter DJ, Smith-Moland E, Goering RV, Hanson 
ND, Lister PD. Multidrug resistance associated with 
mexxy  expression  in  clinical  isolates  of 
pseudomonas  aeruginosa  from  a  texas  hospital. 
Diagn Microbiol Infect Dis 2004;50(1):43-50. 
9.  Pai  H,  Kim  J,  Lee  JH,  Choe  KW,  Gotoh  N. 
Carbapenem  resistance  mechanisms  in  
|  125 
Doripenem versus Old Carbapenems in Pseudomonas Aeruginosa 
Advanced Pharmaceutical Bulletin, 2013, 3(1), 121-125 
 
Copyright © 2013 by Tabriz University of Medical Sciences 
pseudomonas  aeruginosa  clinical  isolates. 
Antimicrob Agents Chemother 2001;45(2):480-4. 
10.  Livermore  DM.  Of  pseudomonas,  porins,  pumps 
and  carbapenems.  J  Antimicrob  Chemother 
2001;47(3):247-50. 
11.Rice  LB.  Challenges  in  identifying  new 
antimicrobial agents effective for treating infections 
with  acinetobacter  baumannii  and  pseudomonas 
aeruginosa. Clin Infect Dis 2006;43 Suppl 2:S100-5. 
12.  Clinical  and  Laboratory  Standards  Institute. 
Performance  standards  for  antimicrobial 
susceptibility  testing;  19th  informational 
supplement.  CLSI  document  M100-S19.  Wayne 
PA: CLSI; 2009. 
13.  Castanheira  M,  Jones  RN,  Livermore  DM. 
Antimicrobial  activities  of  doripenem  and  other 
carbapenems  against  pseudomonas  aeruginosa, 
other  nonfermentative  bacilli,  and  aeromonas  spp. 
Diagn Microbiol Infect Dis 2009;63(4):426-33. 
14. Smith JA, Henry D, Ngui-Yen J, Castell A, Coderre 
S. Comparison of agar dilution, microdilution, and 
disk elution methods for measuring the synergy of 
cefotaxime and its metabolite against anaerobes. J 
Clin Microbiol 1986;23(6):1104-8. 
15. Bou G, Cervero G, Dominguez MA, Quereda C, 
Martinez-Beltran  J.  Pcr-based  DNA  fingerprinting 
(rep-pcr,  ap-pcr)  and  pulsed-field  gel 
electrophoresis  characterization  of  a  nosocomial 
outbreak  caused  by  imipenem-  and  meropenem-
resistant  acinetobacter  baumannii.  Clin  Microbiol 
Infect 2000;6(12):635-43. 
16.  Traczewski  MM,  Brown  SD.  In  vitro  activity  of 
doripenem  against  pseudomonas  aeruginosa  and 
burkholderia  cepacia  isolates  from  both  cystic 
fibrosis and non-cystic fibrosis patients. Antimicrob 
Agents Chemother 2006;50(2):819-21. 
17. Paterson DL, Depestel DD. Doripenem. Clin Infect 
Dis 2009;49(2):291-8.  
18. Quale J, Bratu S, Gupta J, Landman D. Interplay of 
efflux  system,  ampc,  and  oprd  expression  in 
carbapenem resistance of pseudomonas aeruginosa 
clinical  isolates.  Antimicrob  Agents  Chemother 
2006;50(5):1633-41. 
 